Virpax Pharmaceuticals is a preclinical-stage biopharmaceutical company with no approved products and no revenue, focused on developing non-opioid pain management and CNS disorder treatments using proprietary drug delivery technologies. Its two lead candidates are Probudur, a liposomal formulation of bupivacaine injected at surgical wound sites to provide postoperative pain relief, and Envelta, an intranasal spray that delivers enkephalin across the blood-brain barrier to provide morphine-like pain relief without opioid addiction risks. Virpax targets IND filings for Probudur in 2025 and Envelta in 2026, both still years from potential approval. Three earlier-stage candidates — NobrXiol (intranasal CBD for pediatric epilepsy), Epoladerm (topical diclofenac for osteoarthritis), and AnQlar (antiviral nasal spray) — round out the pipeline, with the latter two being actively out-licensed rather than developed internally. Virpax has just 2 full-time employees and outsources all R&D to contract research organizations. The company plans to commercialize any approved products through partnerships rather than building its own sales force. Virpax funds operations entirely through equity offerings and debt, and its auditors have issued going concern opinions for both FY2023 and FY2024. The company is also out of compliance with Nasdaq's minimum stockholders' equity requirement, and recent equity raises have been at deeply diluted terms.